Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

PHASE I/II CLINICAL TRIAL OF SYS6088 INJECTION FOR THE TREATMENT OF ADVANCED SOLID TUMOURS OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA

The Board of Directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the Phase I/II clinical trial (SYS6088-001) of SYS6088 injection (the "**Product**") developed by the Group for the treatment of advanced solid tumours has been officially initiated at the first centre in China.

The Product is a recombinant humanised trispecific antibody targeting programmed cell death protein 1 ("**PD-1**"), vascular endothelial growth factor A ("**VEGFA**") and cytotoxic T lymphocyte associated antigen 4 ("**CTLA-4**"). It can specifically bind to PD-1 and CTLA-4 on the surface of T cell membranes and to VEGFA in the tumour microenvironment, thereby restoring the killing function of T lymphocytes (T cells) and inhibiting angiogenesis in the tumour microenvironment, as well as promoting the activation and expansion of T cells during the immune priming phase, exerting a triple synergistic anti-tumour effect. Fc engineering mitigates the toxicity risk of the Product and effectively prolongs its half-life.

The Group received the Notice of Approval for Clinical Trial of Drug issued by the National Medical Products Administration of the People's Republic of China in October 2026, and initiated the Phase I clinical trial of the Product following the approval. The Phase I/II clinical trial initiated this time is a first-in-human study designed to evaluate the safety, tolerability, pharmacokinetic (PK) profiles and preliminary anti-tumour efficacy of the Product in patients with advanced solid tumours. Currently, participant recruitment and screening for this clinical trial are actively underway.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 3 November 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.